Serum protease-activated receptor (PAR-1) levels as a potential biomarker for diagnosis of inflammation in type 2 diabetic patients.
Biomarker
Cytokines
Inflammation
Protease-activated receptor 1
Type 2 diabetes mellitus
Journal
Inflammopharmacology
ISSN: 1568-5608
Titre abrégé: Inflammopharmacology
Pays: Switzerland
ID NLM: 9112626
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
received:
14
06
2022
accepted:
03
08
2022
pubmed:
17
8
2022
medline:
28
9
2022
entrez:
16
8
2022
Statut:
ppublish
Résumé
Inflammation is a prominent clinical manifestation in type 2 diabetes mellitus (T The present study has been designed to check the serum levels of PAR-1 and correlate with various clinical manifestations and inflammatory cytokines levels in type 2 diabetic subjects. The study population was divided into two groups, healthy volunteers (n = 15): normal glycated hemoglobin (HbA1c) (4.26 ± 0.55) and type 2 diabetic subjects (n = 30): HbA1c levels (7.80 ± 2.41). The serum levels of PAR-1 (ELISA method) were studied in both groups and correlated with demographic parameters age, weight, body mass index (BMI), and conventional inflammation biomarkers like C-reactive protein (CRP), interleukin 6 (IL-6), interleukin 8 (IL-8), and tumour necrosis factor-alpha (TNF-α). The demographic variables including the body weight (77.38 ± 10.00 vs. controls 55.26 ± 6.99), BMI (29.39 ± 3.61 vs. controls 25.25 ± 4.01), glycemic index HbA1c (7.80 ± 2.41 vs. controls 4.26 ± 0.55) were found to be statistically increased in T Our findings indicate that the elevated serum PAR-1 levels serve as an independent predictor of inflammation in T
Sections du résumé
BACKGROUND
BACKGROUND
Inflammation is a prominent clinical manifestation in type 2 diabetes mellitus (T
AIM OF THE STUDY
OBJECTIVE
The present study has been designed to check the serum levels of PAR-1 and correlate with various clinical manifestations and inflammatory cytokines levels in type 2 diabetic subjects.
MATERIAL AND METHODS
METHODS
The study population was divided into two groups, healthy volunteers (n = 15): normal glycated hemoglobin (HbA1c) (4.26 ± 0.55) and type 2 diabetic subjects (n = 30): HbA1c levels (7.80 ± 2.41). The serum levels of PAR-1 (ELISA method) were studied in both groups and correlated with demographic parameters age, weight, body mass index (BMI), and conventional inflammation biomarkers like C-reactive protein (CRP), interleukin 6 (IL-6), interleukin 8 (IL-8), and tumour necrosis factor-alpha (TNF-α).
RESULTS
RESULTS
The demographic variables including the body weight (77.38 ± 10.00 vs. controls 55.26 ± 6.99), BMI (29.39 ± 3.61 vs. controls 25.25 ± 4.01), glycemic index HbA1c (7.80 ± 2.41 vs. controls 4.26 ± 0.55) were found to be statistically increased in T
CONCLUSION
CONCLUSIONS
Our findings indicate that the elevated serum PAR-1 levels serve as an independent predictor of inflammation in T
Identifiants
pubmed: 35974263
doi: 10.1007/s10787-022-01049-0
pii: 10.1007/s10787-022-01049-0
doi:
Substances chimiques
Biomarkers
0
Blood Glucose
0
Cytokines
0
Glycated Hemoglobin A
0
Interleukin-6
0
Interleukin-8
0
Receptor, PAR-1
0
Tumor Necrosis Factor-alpha
0
C-Reactive Protein
9007-41-4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1843-1851Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Antoniak S, Cardenas JC, Buczek LJ et al (2017) Protease-activated receptor 1 contributes to angiotensin II-induced cardiovascular remodeling and inflammation. Cardiology 136(4):258–268. https://doi.org/10.1159/000452269
doi: 10.1159/000452269
pubmed: 27880950
Asokananthan N, Graham PT, Fink J et al (2002) Activation of protease-activated receptor (PAR)-1, PAR-2, and PAR-4 stimulates IL-6, IL-8, and prostaglandin E2 release from human respiratory epithelial cells. J Immunol 168(7):3577–3585. https://doi.org/10.4049/jimmunol.168.7.3577
doi: 10.4049/jimmunol.168.7.3577
pubmed: 11907122
Austin KM, Covic L, Kuliopulos A (2013) Matrix metalloproteases and PAR1 activation. Blood, J Hematol Am Soc 121(3):431–439
Calle MC, Fernandez ML (2012) Inflammation and type 2 diabetes. Diabetes Metab 38(3):183–191. https://doi.org/10.1016/j.diabet.2011.11.006
doi: 10.1016/j.diabet.2011.11.006
pubmed: 22252015
Chen H, Smith M, Herz J et al (2021) The role of protease-activated receptor 1 signaling in CD8 T cell effector functions. Iscience 24(11):103387. https://doi.org/10.1016/j.isci.2021.103387
doi: 10.1016/j.isci.2021.103387
pubmed: 34841225
pmcid: 8605340
Cunningham MA, Rondeau E, Chen X et al (2000) Protease-activated receptor 1 mediates thrombin-dependent, cell-mediated renal inflammation in crescentic glomerulonephritis. J Exp Med 191(3):455–462. https://doi.org/10.1084/jem.191.3.455
doi: 10.1084/jem.191.3.455
pubmed: 10662791
pmcid: 2195821
De Beer FC, Hind CR, Fox KM et al (1982) Measurement of serum C-reactive protein concentration in myocardial ischaemia and infarction. Heart 47(3):239–243. https://doi.org/10.1136/hrt.47.3.239
doi: 10.1136/hrt.47.3.239
de Jager J, Dekker JM, Kooy A et al (2006) Endothelial dysfunction and low-grade inflammation explain much of the excess cardiovascular mortality in individuals with type 2 diabetes: the Hoorn study. Arterioscler Thromb Vasc Biol 26(5):1086–1093. https://doi.org/10.1161/01.ATV.0000215951.36219.a4
doi: 10.1161/01.ATV.0000215951.36219.a4
pubmed: 16514084
DeFronzo RA, Ferrannini E, Groop L et al (2015) Type 2 diabetes mellitus. Nat Rev Dis Primers 1(1):1–22. https://doi.org/10.1038/nrdp.2015.19
doi: 10.1038/nrdp.2015.19
Dobrica E, Gaman MA, Cozma MA, Gaman AM, Diaconu CC (2019) Macrovascular and microvascular complications in type 2 diabetes mellitus: did hypertension change the setting? J Hypertens 37:e140–e141. https://doi.org/10.1097/01.hjh.0000571816.00025.b3
doi: 10.1097/01.hjh.0000571816.00025.b3
El Sheikh WM, Alahmar IE, Salem GM, El-Sheikh MA (2019) Tumor necrosis factor alpha in peripheral neuropathy in type 2 diabetes mellitus. Egypt J Neurol Psychiatry Neurosurg 55(1):1–7. https://doi.org/10.1186/s41983-019-0080-0
doi: 10.1186/s41983-019-0080-0
El-Edel RH, Fathy WM, Abou-Elela DH, Emara MM, El-Khair NT (2020) Role of tumor necrosis factor alpha in type 2 diabetic nephropathy. Menoufia Med J 33(3):920. https://doi.org/10.4103/mmj.mmj_430_18
doi: 10.4103/mmj.mmj_430_18
Fan Y, Zhang W, Mulholland M (2005) Thrombin and PAR-1-AP increase proinflammatory cytokine expression in C6 cells1. J Surg Res 129(2):196–201. https://doi.org/10.1016/j.jss.2005.07.041
doi: 10.1016/j.jss.2005.07.041
pubmed: 16143343
Fang X, Liao R, Yu Y, Li J, Guo Z, Zhu T (2019) Thrombin induces secretion of multiple cytokines and expression of protease-activated receptors in mouse mast cell line. Mediat Inflamm. https://doi.org/10.1155/2019/4952131
doi: 10.1155/2019/4952131
Fowler MJ (2008) Microvascular and macrovascular complications of diabetes. Clin Diabetes 26(2):77–82. https://doi.org/10.2337/diaclin.26.2.77
doi: 10.2337/diaclin.26.2.77
Galicia-Garcia U, Benito-Vicente A, Jebari S et al (2020) Pathophysiology of type 2 diabetes mellitus. Int J Mol Sci 21(17):6275. https://doi.org/10.3390/ijms21176275
doi: 10.3390/ijms21176275
pmcid: 7503727
Ganz ML, Wintfeld N, Li Q et al (2014) The association of body mass index with the risk of type 2 diabetes: a case–control study nested in an electronic health records system in the United States. Diabetol Metab Syndr 6(1):1–8. https://doi.org/10.1186/1758-5996-6-50
doi: 10.1186/1758-5996-6-50
Ghouse J, Isaksen JL, Skov MW et al (2020) Effect of diabetes duration on the relationship between glycaemic control and risk of death in older adults with type 2 diabetes. Diabetes Obes Metab 22(2):231–242. https://doi.org/10.1111/dom.13891
doi: 10.1111/dom.13891
pubmed: 31596048
Gray N, Picone G, Sloan F, Yashkin A (2015) The relationship between BMI and onset of diabetes mellitus and its complications. South Med J 108(1):29. https://doi.org/10.14423/SMJ.0000000000000214
doi: 10.14423/SMJ.0000000000000214
pubmed: 25580754
pmcid: 4457375
Guh DP, Zhang W, Bansback N et al (2009) The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health 9(1):1–20. https://doi.org/10.1186/1471-2458-9-88
doi: 10.1186/1471-2458-9-88
Gupta R, Pamecha H (2020) To study relationship of serum hsCRP with type 2 diabetes mellitus, its vascular complications and non-diabetics-case control study. J Assoc Phys India 68(8):25–29
Heuberger DM, Schuepbach RA (2019) Protease-activated receptors (PARs): mechanisms of action and potential therapeutic modulators in PAR-driven inflammatory diseases. Thrombosis J 17:4. https://doi.org/10.1186/s12959-019-0194-8
doi: 10.1186/s12959-019-0194-8
Hurley A, Smith M, Karpova T et al (2013) Enhanced effector function of CD8+ T cells from healthy controls and HIV-infected patients occurs through thrombin activation of protease-activated receptor 1. J Infect Dis 207(4):638–650. https://doi.org/10.1093/infdis/jis730
doi: 10.1093/infdis/jis730
pubmed: 23204166
Junge CE, Sugawara T, Mannaioni G et al (2003) The contribution of protease-activated receptor 1 to neuronal damage caused by transient focal cerebral ischemia. Proc Natl Acad Sci 100(22):13019–13024. https://doi.org/10.1073/pnas.2235594100
doi: 10.1073/pnas.2235594100
pubmed: 14559973
pmcid: 240737
Kahn ML, Nakanishi-Matsui M, Shapiro MJ, Ishihara H, Coughlin SR (1999) Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Investig 103(6):879–887. https://doi.org/10.1172/JCI6042
doi: 10.1172/JCI6042
pubmed: 10079109
pmcid: 408153
Kanmani S, Kwon M, Shin MK, Kim MK (2019) Association of C-reactive protein with risk of developing type 2 diabetes mellitus, and role of obesity and hypertension: a large population-based Korean cohort study. Sci Rep 9(1):1–8. https://doi.org/10.1038/s41598-019-40987-8
doi: 10.1038/s41598-019-40987-8
Lee PR, Johnson TP, Gnanapavan S et al (2017) Protease-activated receptor-1 activation by granzyme B causes neurotoxicity that is augmented by interleukin-1β. J Neuroinflammation 14(1):1–8. https://doi.org/10.1186/s12974-017-0901-y
doi: 10.1186/s12974-017-0901-y
Lintermans LL, Stegeman CA, Heeringa P, Abdulahad WH (2014) T cells in vascular inflammatory diseases. Front Immunol 5:504. https://doi.org/10.3389/fimmu.2014.00504
doi: 10.3389/fimmu.2014.00504
pubmed: 25352848
pmcid: 4196542
Liu X, Yu J, Song S, Yue X, Li Q (2017) Protease-activated receptor-1 (PAR-1): a promising molecular target for cancer. Oncotarget 8(63):107334
doi: 10.18632/oncotarget.21015
Liu Y, Tang ZZ, Zhang YM et al (2020) Thrombin/PAR-1 activation induces endothelial damages via NLRP1 inflammasome in gestational diabetes. Biochem Pharmacol 175:113849. https://doi.org/10.1016/j.bcp.2020.113849
doi: 10.1016/j.bcp.2020.113849
pubmed: 32059841
Mari B, Imbert V, Belhacene N et al (1994) Thrombin and thrombin receptor agonist peptide induce early events of T cell activation and synergize with TCR cross-linking for CD69 expression and interleukin 2 production. J Biol Chem 269(11):8517–8523. https://doi.org/10.1016/S0021-9258(17)37225-3
doi: 10.1016/S0021-9258(17)37225-3
pubmed: 7510689
Navale AM, Paranjape AN (2013) Role of inflammation in development of diabetic complications and commonly used inflammatory markers with respect to diabetic complications. Int J Pharm Pharm Sci 5(Suppl 2):1–5
Nazari A, Sardoo AM, Fard ET et al (2017) Is IL-6 increased in type 2 diabetes mellitus patients independent of nephropathic complication. Endocrinol Diabetes Obes 5(2):1102
Pan A, Wang Y, Yuan JM, Koh WP (2017) High-sensitive C-reactive protein and risk of incident type 2 diabetes: a case–control study nested within the Singapore Chinese Health Study. BMC Endocr Disord 17(1):1–8. https://doi.org/10.1186/s12902-017-0159-5
doi: 10.1186/s12902-017-0159-5
Pawlinski R, Tencati M, Hampton CR et al (2007) Protease-activated receptor-1 contributes to cardiac remodeling and hypertrophy. Circulation 116(20):2298–2306. https://doi.org/10.1161/CIRCULATIONAHA.107.692764
doi: 10.1161/CIRCULATIONAHA.107.692764
pubmed: 17967980
pmcid: 2848478
Pradeepa R, Mohan V (2021) Epidemiology of type 2 diabetes in India. Indian J Ophthalmol 69(11):2932. https://doi.org/10.4103/ijo.IJO_1627_21
doi: 10.4103/ijo.IJO_1627_21
pubmed: 34708726
pmcid: 8725109
Randeria SN, Thomson GJ, Nell TA, Roberts T, Pretorius E (2019) Inflammatory cytokines in type 2 diabetes mellitus as facilitators of hypercoagulation and abnormal clot formation. Cardiovasc Diabetol 18(1):1–5. https://doi.org/10.1186/s12933-019-0870-9
doi: 10.1186/s12933-019-0870-9
Reddy S, Amutha A, Rajalakshmi R et al (2017) Association of increased levels of MCP-1 and cathepsin-D in young onset type 2 diabetes patients (T2DM-Y) with severity of diabetic retinopathy. J Diabetes Complicat 31(5):804–809. https://doi.org/10.1016/j.jdiacomp.2017.02.017
doi: 10.1016/j.jdiacomp.2017.02.017
Roudbary SA, Saadat F, Forghanparast K, Sohrabnejad R (2011) Serum C-reactive protein level as a biomarker for differentiation of ischemic from hemorrhagic stroke. Acta Med Iran 49:149–152
pubmed: 21681701
Saeed MA, Ng GZ, Däbritz J et al (2017) Protease-activated receptor 1 plays a proinflammatory role in colitis by promoting Th17-related immunity. Inflamm Bowel Dis 23(4):593–602. https://doi.org/10.1097/MIB.0000000000001045
doi: 10.1097/MIB.0000000000001045
pubmed: 28296821
Sassy-Prigent C, Heudes D, Mandet C et al (2000) Early glomerular macrophage recruitment in streptozotocin-induced diabetic rats. Diabetes 49(3):466–475. https://doi.org/10.2337/diabetes.49.3.466
doi: 10.2337/diabetes.49.3.466
pubmed: 10868970
Satoh J, Yagihashi S, Toyota T (2003) The possible role of tumor necrosis factor-α in diabetic polyneuropathy. Exp Diabesity Res 4(2):65–71. https://doi.org/10.1155/EDR.2003.65
doi: 10.1155/EDR.2003.65
pubmed: 14630568
pmcid: 2478597
Schoergenhofer C, Schwameis M, Gelbenegger G et al (2018) Inhibition of protease-activated receptor (PAR1) reduces activation of the endothelium, coagulation, fibrinolysis and inflammation during human endotoxemia. Thromb Haemost 118(07):1176–1184. https://doi.org/10.1055/s-0038-1655767
doi: 10.1055/s-0038-1655767
pubmed: 29864779
Shadick NA, Cook NR, Karlson EW et al (2006) C-reactive protein in the prediction of rheumatoid arthritis in women. Arch Intern Med 166(22):2490–2494. https://doi.org/10.1001/archinte.166.22.2490
doi: 10.1001/archinte.166.22.2490
pubmed: 17159015
Shavit-Stein E, Gofrit SG, Gayster A et al (2020) Treatment of diabetic neuropathy with a novel PAR1-targeting molecule. Biomolecules 10(11):1552. https://doi.org/10.3390/biom10111552
doi: 10.3390/biom10111552
pmcid: 7698286
Smail MM, Howarth CF, Singh J, Ismail AM (2019) Inflammation and diabetic cardiomyopathy. In: Aronow WS, Murashita T (eds) Inflammatory heart diseases. IntechOpen, London
Spranger J, Kroke A, Mohlig M et al (2003) Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European prospective investigation into cancer and nutrition (EPIC)-Potsdam study. Diabetes 52(3):812–817. https://doi.org/10.2337/diabetes.52.3.812
doi: 10.2337/diabetes.52.3.812
pubmed: 12606524
Swaroop JJ, Rajarajeswari D, Naidu JN (2012) Association of TNF-α with insulin resistance in type 2 diabetes mellitus. Indian J Med Res 135(1):127. https://doi.org/10.4103/0971-5916.93435
doi: 10.4103/0971-5916.93435
pubmed: 22382194
pmcid: 3307173
Thorand B, Löwel H, Schneider A et al (2003) C-reactive protein as a predictor for incident diabetes mellitus among middle-aged men: results from the MONICA Augsburg cohort study, 1984–1998. Arch Intern Med 163(1):93–99. https://doi.org/10.1001/archinte.163.1.93
doi: 10.1001/archinte.163.1.93
pubmed: 12523922
Tognetto M, D’Andrea MR, Trevisani M et al (2003) Proteinase-activated receptor-1 (PAR-1) activation contracts the isolated human renal artery in vitro. Br J Pharmacol 139(1):21–27
doi: 10.1038/sj.bjp.0705215
Tsalamandris S, Antonopoulos AS, Oikonomou E et al (2019) The role of inflammation in diabetes: current concepts and future perspectives. Eur Cardiol Rev 14(1):50
doi: 10.15420/ecr.2018.33.1
Waasdorp M, Florquin S, Duitman J, Spek CA (2019) Pharmacological PAR-1 inhibition reduces blood glucose levels but does not improve kidney function in experimental type 2 diabetic nephropathy. FASEB J 33(10):10966–10972. https://doi.org/10.1096/fj.201900516R
doi: 10.1096/fj.201900516R
pubmed: 31287960
Willis Fox O, Preston RJ (2020) Molecular basis of protease-activated receptor 1 signaling diversity. J Thromb Haemost 18(1):6–16. https://doi.org/10.1111/jth.14643
doi: 10.1111/jth.14643
pubmed: 31549766
World Health Organization (2022) https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death . Accessed 20 May 2022
Zieske AW, Tracy RP, McMahan CA et al (2005) Elevated serum C-reactive protein levels and advanced atherosclerosis in youth. Arterioscler Thromb Vasc Biol 25(6):1237–1243. https://doi.org/10.1161/01.ATV.0000164625.93129.64
doi: 10.1161/01.ATV.0000164625.93129.64
pubmed: 15802624